Gene · 4277
Papers3,381
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 3,381
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. | Nat Cancer | 2023 | 37537301 | PubTator, text mining | PubMed |
| T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment. | Int J Mol Sci | 2023 | 37511431 | PubTator, text mining | PubMed |
| Scaffold-Based (Matrigel™) 3D Culture Technique of Glioblastoma Recovers a Patient-like Immunosuppressive Phenotype. | Cells | 2023 | 37508520 | PubTator, text mining | PubMed |
| Integrated multiple-microarray analysis and mendelian randomization to identify novel targets involved in diabetic nephropathy. | Front Endocrinol (Lausanne) | 2023 | 37492198 | PubTator, text mining | PubMed |
| Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential. | Front Immunol | 2023 | 37483603 | PubTator, text mining | PubMed |
| Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma. | Eur J Med Res | 2023 | 37481601 | PubTator, text mining | PubMed |
| Responsiveness to endurance training can be partly explained by the number of favorable single nucleotide polymorphisms an individual possesses. | PLoS One | 2023 | 37471354 | PubTator, text mining | PubMed |
| Defining the role of natural killer cells in COVID-19. | Nat Immunol | 2023 | 37460639 | PubTator, text mining | PubMed |
| NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells. | Cell Death Dis | 2023 | 37460534 | PubTator, text mining | PubMed |
| Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma. | Front Immunol | 2023 | 37457718 | PubTator, text mining | PubMed |
| Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. | Br J Cancer | 2023 | 37454231 | PubTator, text mining | PubMed |
| Novel Genetic Risk Variants and Clinical Predictors Associated With Primary Sclerosing Cholangitis in Patients With Ulcerative Colitis. | Clin Transl Gastroenterol | 2023 | 37440754 | PubTator, text mining | PubMed |
| Natural killer cells in the lung: potential role in asthma and virus-induced exacerbation? | Eur Respir Rev | 2023 | 37437915 | PubTator, text mining | PubMed |
| Effects of sevoflurane on metalloproteinase and natural killer group 2, member D (NKG2D) ligand expression and natural killer cell-mediated cytotoxicity in breast cancer: an in vitro study. | Korean J Anesthesiol | 2023 | 37435613 | PubTator, text mining | PubMed |
| AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation. | Front Immunol | 2023 | 37435061 | PubTator, text mining | PubMed |
| Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution. | Front Oncol | 2023 | 37427097 | PubTator, text mining | PubMed |
| γδ T cells in immunotherapies for B-cell malignancies. | Front Immunol | 2023 | 37426670 | PubTator, text mining | PubMed |
| Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. | Front Immunol | 2023 | 37426654 | PubTator, text mining | PubMed |
| Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential. | Front Cell Infect Microbiol | 2023 | 37424781 | PubTator, text mining | PubMed |
| Crosstalk between autophagy and CSCs: molecular mechanisms and translational implications. | Cell Death Dis | 2023 | 37422448 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4277/papers?page=17